MA63064A1 - Anticorps anti-tmprss6 et leurs utilisations - Google Patents

Anticorps anti-tmprss6 et leurs utilisations

Info

Publication number
MA63064A1
MA63064A1 MA63064A MA63064A MA63064A1 MA 63064 A1 MA63064 A1 MA 63064A1 MA 63064 A MA63064 A MA 63064A MA 63064 A MA63064 A MA 63064A MA 63064 A1 MA63064 A1 MA 63064A1
Authority
MA
Morocco
Prior art keywords
antibodies
tmprss6
bind
disorder
humans
Prior art date
Application number
MA63064A
Other languages
English (en)
Other versions
MA63064B1 (fr
Inventor
Andrew J Murphy
William Olson
Sarah J Hatsell
Harvey Chin
Heinrich Emil Lob
Kei Saotome
Bojie Zhang
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA63064A1 publication Critical patent/MA63064A1/fr
Publication of MA63064B1 publication Critical patent/MA63064B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des anticorps monoclonaux qui se lient à la protéine sérine protéase transmembranaire 6 (tmprss6), ainsi que leurs procédés d'utilisation. Dans divers modes de réalisation de l'invention, les anticorps sont des anticorps entièrement humains qui se lient à la tmprss6. Dans certains modes de réalisation, les anticorps de l'invention sont utiles dans une méthode de traitement ou de prévention d'une maladie, d'un trouble ou d'une affection associé à tmprss6 chez l'être humain.
MA63064A 2021-05-11 2022-05-10 Anticorps anti-tmprss6 et leurs utilisations MA63064B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163187150P 2021-05-11 2021-05-11
PCT/US2022/028595 WO2022240877A1 (fr) 2021-05-11 2022-05-10 Anticorps anti-tmprss6 et leurs utilisations

Publications (2)

Publication Number Publication Date
MA63064A1 true MA63064A1 (fr) 2024-02-29
MA63064B1 MA63064B1 (fr) 2025-02-28

Family

ID=81927373

Family Applications (1)

Application Number Title Priority Date Filing Date
MA63064A MA63064B1 (fr) 2021-05-11 2022-05-10 Anticorps anti-tmprss6 et leurs utilisations

Country Status (14)

Country Link
US (2) US12448435B2 (fr)
EP (1) EP4337695A1 (fr)
JP (1) JP2024517931A (fr)
KR (1) KR20240005894A (fr)
CN (1) CN117730099A (fr)
AU (1) AU2022274888A1 (fr)
BR (1) BR112023023558A2 (fr)
CA (1) CA3218455A1 (fr)
CL (1) CL2023003331A1 (fr)
CO (1) CO2023016777A2 (fr)
IL (1) IL308375A (fr)
MA (1) MA63064B1 (fr)
MX (1) MX2023013248A (fr)
WO (1) WO2022240877A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4337695A1 (fr) 2021-05-11 2024-03-20 Regeneron Pharmaceuticals, Inc. Anticorps anti-tmprss6 et leurs utilisations
WO2024211404A2 (fr) * 2023-04-04 2024-10-10 Disc Medicine, Inc. Anticorps anti-tmprss6 et leurs utilisations
WO2025245434A1 (fr) * 2024-05-24 2025-11-27 Disc Medicine, Inc. Compositions et méthodes de traitement de syndromes myélodysplasiques (mds)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (fr) 2004-04-20 2005-11-03 Genmab A/S Anticorps monoclonaux humains diriges contre cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
GB0916576D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
CN108026582A (zh) * 2015-07-31 2018-05-11 米迪缪尼有限公司 用于治疗海帕西啶介导的病症的方法
WO2021105389A1 (fr) * 2019-11-29 2021-06-03 Kymab Limited Traitement de surcharge de fer physiologique
US12215170B2 (en) * 2020-04-07 2025-02-04 Mabwell Therapeutics Inc. Anti-TMPRSS6 antibodies and uses thereof
EP4337695A1 (fr) 2021-05-11 2024-03-20 Regeneron Pharmaceuticals, Inc. Anticorps anti-tmprss6 et leurs utilisations

Also Published As

Publication number Publication date
BR112023023558A2 (pt) 2024-03-12
WO2022240877A1 (fr) 2022-11-17
AU2022274888A1 (en) 2023-12-07
JP2024517931A (ja) 2024-04-23
CO2023016777A2 (es) 2023-12-11
IL308375A (en) 2024-01-01
MA63064B1 (fr) 2025-02-28
CL2023003331A1 (es) 2024-06-07
CA3218455A1 (fr) 2022-11-17
MX2023013248A (es) 2024-01-29
KR20240005894A (ko) 2024-01-12
US20220411487A1 (en) 2022-12-29
EP4337695A1 (fr) 2024-03-20
US12448435B2 (en) 2025-10-21
CN117730099A (zh) 2024-03-19
US20260098084A1 (en) 2026-04-09

Similar Documents

Publication Publication Date Title
MA63064A1 (fr) Anticorps anti-tmprss6 et leurs utilisations
MA54405B1 (fr) Anticorps de la glycoprotéine de spicule anti-sras-cov-2 et fragments de liaison à l'antigène
MA32566B1 (fr) Anticorps neutralisant les cytomégalovirus humains et leurs utilisations
MA31225B1 (fr) Anticorps neutralisants des cytomegalovirus humains et leur utilisation
WO2003106498A3 (fr) Molecules de liaison agonistes au recepteur ox40 humain
MA32577B1 (fr) Anticorps neutralisants le virus de l'influenza a et leurs utilisations
MA46619B1 (fr) Anticorps anti-il-33 et leurs utilisations
MA35620B1 (fr) Compositions pour le traitement de l'arthrite rhumatoïde et procédés d'utilisation desdites compositions
MA32561B1 (fr) Anticorps neutralisant le cytomegalovirus humain et leurs utilisations
MA30353B1 (fr) Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes.
MA35345B1 (fr) Proteines de liaisons a un antigene ayant une liaison accrue a fcrn
ATE263189T1 (de) Antikörper gegen menschliches prostatspezifisches drüsenkallikrein
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
MA52962B1 (fr) Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1
WO2003104273A3 (fr) Epitopes therapeutiques et leurs utilisations
MA53689B1 (fr) Anticorps humanisés contre un fragment bêta d'une chaîne de la famille 9 du récepteur cellulaire trbv-9 de l'humain et méthodes de leur application
MA53688A1 (fr) Anticorps monoclonaux qui se lient spécifiquement à trbv-9 de l'humain
EP4112722A4 (fr) Souche cellulaire d'hybridome anti-vim carbapénémase, anticorps monoclonal et application
EP4265717A4 (fr) Souche cellulaire d'hybridome protéique anti-mcr-1/mcr-2 de souris, anticorps monoclonal et utilisation
CA3156096A1 (fr) Agents liants doubles pd1 et vegfr2
DE69322783D1 (de) Monoklonale Antikörper gegen Glykoprotein P
EP4261278A4 (fr) Souche cellulaire d'hybridome de souris anti-ndm carbapénémase, anticorps monoclonal et utilisation
FR3109779B1 (fr) Anticorps et ses utilisations
ATE202117T1 (de) Angiotensin ii rezeptor typ i spezifische monoklonale antikörper und hybridoma
Casarini et al. Calcium Channel Blockers as Inhibitors of Angiotensin I–Converting Enzyme